Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (RGEN) drives innovation in bioprocessing technologies critical for biologics manufacturing, serving pharmaceutical companies and CDMOs worldwide. This page provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access comprehensive coverage of Repligen's strategic initiatives, including financial results, product innovations, and partnership announcements. Our curated news collection enables stakeholders to track the company's impact on biomanufacturing efficiency and therapeutic development pipelines.
Explore updates across key operational areas: quarterly earnings disclosures, regulatory milestones for filtration systems and chromatography products, R&D advancements in process analytics, and global expansion efforts. Content is rigorously verified to ensure alignment with market-moving developments.
Bookmark this page for streamlined access to Repligen's evolving market position. Regularly updated coverage supports informed analysis of the company's role in advancing next-generation drug manufacturing technologies.
Repligen (NASDAQ:RGEN) has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025. The company will release its earnings press release before market opening, followed by a conference call at 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2025.
The conference call will be accessible via toll-free numbers: (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. A webcast will also be available through the company's Investor Relations website. Replay options include dial-in numbers (877) 344-7529 (US), (855) 669-9658 (Canada), and (412) 317-0088 (international) with passcode 6386085.
Repligen (NASDAQ:RGEN) has appointed Jacob Johnson as Vice President of Investor Relations. Johnson, who previously served as Managing Director and Research Analyst at Stephens Inc., will lead investor relations and report to CFO Jason K. Garland.
Johnson brings significant experience in the life sciences tools and pharma services sector, having covered Repligen as a research analyst since 2019. He previously worked as a research associate on Stephens' healthcare services team and in investment management. Johnson holds a B.A. in Economics and Mathematics from Sewanee and an M.S. Finance from Washington University's Olin Business School.
He succeeds Sondra Newman, who is retiring after leading global investor relations and corporate communications since 2012.
Repligen (RGEN) has acquired a bioprocessing analytics portfolio from 908 Devices for $70 million in cash. The acquisition includes four desktop devices for Process Analytical Technology (PAT) applications: MAVERICK and MAVEN for real-time monitoring and control, REBEL for cell culture media analysis, and ZipChip for product quality characterization.
The strategic purchase strengthens Repligen's PAT portfolio, enabling comprehensive analytics solutions across the entire bioprocess workflow. The acquisition includes the transfer of 908's bioprocessing team to Repligen. Meanwhile, 908 Devices will maintain focus on its handheld device portfolio for health and safety applications.
This transaction represents a significant step in Repligen's strategy to support customers' increasing adoption of digitization technologies in production processes, particularly enhancing their capabilities in upstream and downstream analytics.
Repligen (RGEN) has acquired the desktop bioprocessing analytics portfolio from 908 Devices (MASS) for $70 million in cash. The acquisition includes four PAT (Process Analytical Technology) devices: MAVERICK, MAVEN, REBEL, and ZipChip.
The acquired technologies enable real-time monitoring, control of bioprocess parameters, cell culture media analysis, and high-resolution sample separations for product quality characterization. This strategic move strengthens Repligen's PAT portfolio and expands its capabilities across the entire bioprocess workflow.
Following the transaction, 908 Devices will focus on growing its handheld device portfolio for health and safety applications. The deal includes the transfer of 908's bioprocessing team to Repligen.
Repligen (NASDAQ:RGEN) reported Q4 2024 revenue of $168 million and full-year revenue of $634 million. Q4 orders and revenues showed sequential increases of 11% and 8% respectively, with orders outpacing revenue by 6%. The company experienced strong momentum across its portfolio, with Q4 revenue growing 13% excluding COVID-related revenue, despite currency headwinds.
CDMO and capital equipment segments showed significant sequential growth, with revenues increasing approximately 20% and 30% respectively. The company completed the acquisition of Tantti Laboratory Inc and launched AVIPure® dsRNA resin for mRNA therapeutics.
For Q4 2024, GAAP net loss was $(34) million, with adjusted net income of $25 million. Full-year 2024 GAAP net loss was $(26) million, with adjusted net income of $89 million. The company provided 2025 guidance projecting 8-12% reported growth, or 10-14% excluding COVID-related revenue.
Repligen (NASDAQ:RGEN) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss business updates and financial results for the three- and twelve-month periods ended December 31, 2024.
The conference call will be available via toll-free numbers for domestic and international callers, and a webcast will be accessible through the company's Investor Relations website. Both the call and webcast will be archived for future access, with replay numbers provided for U.S., Canadian, and international callers using passcode 6188777.
Repligen (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13-16 in San Francisco. Olivier Loeillot, President and CEO, will deliver a company overview presentation on Tuesday, January 14 at 1:30 p.m. PT.
The presentation will be accessible via live webcast through Repligen's Investor Relations website at www.repligen.com. A replay option will be available for a time after the event.
Repligen (NASDAQ:RGEN) has launched the CTech™ SoloVPE® PLUS System, an advanced UV-based Variable Pathlength Technology system for biopharmaceutical manufacturers. This next-generation system delivers precise concentration measurements in under 30 seconds without requiring dilution or background correction.
The system addresses the bioprocess industry's shift toward higher drug concentration formulations, offering key advantages including: 70% reduction in process steps, doubled data collection speed, measurement capability for mAbs from 0.01 mg/mL to 320 mg/mL with R²≥ 0.999, and elimination of dilution requirements. Applications include protein concentration measurement, nucleic acids quantitation, and mRNA measurement in therapeutics.
The system integrates with CTech™ ViPER® ANLYTX Software, featuring SQL data storage and OPC-UA communication for real-time access and scalable operations. This launch marks the first of several planned product releases for 2025.
BioLife Solutions (BLFS) has appointed Tony J. Hunt, Executive Chairman of Repligen , to its board of directors effective January 2, 2025, expanding the board to six members. Hunt brings extensive experience in bioprocessing innovation and leadership, having served as Repligen's CEO for nine years before becoming Executive Chairman in September 2024. His prior roles include President of Bioproduction at Life Technologies and Senior Director of Pharma Programs at Applied Biosystems. BioLife Solutions, a leading supplier of cell processing tools for the cell and gene therapy market, aims to leverage Hunt's expertise to strengthen its position in CGT bioprocessing solutions.
Repligen (NASDAQ:RGEN) has published its 2023 Corporate Sustainability Report, titled 'Advancing Impacts.' The report outlines progress across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways.
Key achievements include:
- Expansion of 100% renewable electricity to 13 of 18 manufacturing sites (88% of global consumption)
- Increase in women in management positions from 27% to 29%
- 68% reduction in Scope 2 emissions from 2022 to 2023
- 60% increase in productivity savings through Repligen Performance System
- Commitment to net-zero emissions by 2050 with Science Based Targets initiative
The report aligns with major reporting frameworks including GRI Standards, SASB, UN SDGs, and TCFD, and serves as Repligen's 2023 Communication on Progress for the UN Global Compact.
